Effects of Autogenic Drainage and Flutter Device in COPD

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-60
SponsorRiphah International University

About this trial

COPD is a progressive lung disease that includes emphysema and chronic bronchitis and is a major cause of morbidity and mortality worldwide. Airway clearance techniques help improve mucus removal, reduce dyspnea, and enhance quality of life in COPD patients. This study aims to compare the effects of autogenic drainage and flutter device on dyspnea, pulmonary function, and functional capacity in patients with COPD. A randomized clinical trial will be conducted at Gulab Devi Teaching Hospital using convenient sampling. Participants will be divided into two groups: Group A will receive autogenic drainage, while Group B will use the flutter device. Interventions will be performed daily for 20-30 minutes over 6 weeks. Outcome measures will include dyspnea severity scale, spirometry, and 6-minute walk test. Data will be analyzed using SPSS with significance set at p \< 0.05. The study may provide evidence for effective, non-invasive, and cost-effective management strategies for COPD patients.

Eligibility criteria

Qualifiers

Age group: Middle age adults (40-60 years), medically stable

Both gender

Diagnosis based on GOLD criteria ((FEV₁/FVC ratio < 0.70).

Moderate COPD with no acute exacerbations in the past 4-6 weeks.

Disqualifiers

Cardic Diseases (Acute MI, Congestive Heart Failure)

Musculoskeletal Impairements

Using Non-invasive Ventilation

Recent lung diseases (Respiratory failure, pneumothorax)

Trial design

Treatments tested in this trial

  • Autogenic drainage
  • Flutter Device

Treatment groups

42 Participants
are divided into 2 treatment groups